ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 42 | November 1, 1985

Download PDF Visit The Full Archive

Related Articles

NCI plans 11-16 percent budget cuts in new grants to maintain R01 payline at 20th percentile.

November 28, 2003

IMRT Less Toxic Than 3D-CRT In Localized Prostate Cancer

October 28, 2011

Report Urges Changes To Cut Activation Times For NCI Phase III Trials.

April 9, 2010

Frederick RFP Available Oct. 22; Three Four May Challenge L-B

August 27, 1976

In Brief: More Money For Fewer Grants? Or Spread It Around, Rhoads Asks; AACR To Take Stands

June 10, 1977

Ohio State Wins P01 Grant

December 6, 2002